TimesSquare Capital Management’s Arcus Biosciences RCUS Stock Holding History

TimesSquare Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-822,012	Closed	-$25.9M	–	199
2022 Q1	$25.9M	Sell	822,012 -142,770	-15%	-$4.78M	0.29%	135
2021 Q4	$39M	Buy	964,782 +312,542	+48%	+$12.1M	0.35%	123
2021 Q3	$22.7M	Sell	652,240 -35,300	-5%	-$1.1M	0.2%	163
2021 Q2	$18.9M	Sell	687,540 -32,000	-4%	-$914K	0.15%	182
2021 Q1	$20.2M	Sell	719,540 -107,730	-13%	-$3.75M	0.17%	175
2020 Q4	$21.5M	Sell	827,270 -23,500	-3%	-$569K	0.17%	173
2020 Q3	$14.6M	Sell	850,770 -34,100	-4%	-$762K	0.14%	190
2020 Q2	$21.9M	Buy	+884,870	New	+$23.9M	0.21%	172

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

TimesSquare Capital Management's RCUS Position: Q2 2022 in Review

TimesSquare Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 822,012 shares — an estimated $25.9M sold.

TimesSquare Capital Management first reported a position in RCUS in Q2 2020 and held it in 8 quarters. The position peaked at $39M in Q4 2021. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

TimesSquare Capital Management reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
TimesSquare Capital Management sold 822,012 Arcus Biosciences shares in Q2 2022, an estimated $25.9M.
TimesSquare Capital Management first reported a position in Arcus Biosciences in Q2 2020 and held it in 8 quarters.
TimesSquare Capital Management's Arcus Biosciences position peaked at $39M in Q4 2021.
173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on TimesSquare Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.